Literature DB >> 26796969

Management of Patients With Recovered Systolic Function.

Anupam Basuray1, James C Fang2.   

Abstract

Advancements in the treatment of heart failure (HF) with systolic dysfunction have given rise to a new population of patients with improved ejection fraction (EF). The management of this distinct population is not well described due to a lack of consensus on the definition of myocardial recovery, a scarcity of data on the natural history of these patients, and the absence of focused clinical trials. Moreover, an improvement in EF may have different prognostic and management implications depending on the underlying etiology of cardiomyopathy. This can be challenging for the clinician who is approached by a patient inquiring about a reduction of medical therapy after apparent EF recovery. This review explores management strategies for HF patients with recovered EF in a disease-specific format.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure recovered ejection fraction; Myocardial recovery; Reverse remodeling

Mesh:

Substances:

Year:  2016        PMID: 26796969     DOI: 10.1016/j.pcad.2016.01.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  7 in total

1.  Heart failure with recovered ejection fraction.

Authors:  Kazuaki Tanabe; Takahiro Sakamoto
Journal:  J Echocardiogr       Date:  2018-09-14

Review 2.  Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery.

Authors:  Karolina K Marinescu; Nir Uriel; Douglas L Mann; Daniel Burkhoff
Journal:  Expert Rev Med Devices       Date:  2016-12-22       Impact factor: 3.166

Review 3.  Reverse remodelling and myocardial recovery in heart failure.

Authors:  Gene H Kim; Nir Uriel; Daniel Burkhoff
Journal:  Nat Rev Cardiol       Date:  2017-09-21       Impact factor: 32.419

Review 4.  Heart Failure with Recovered EF and Heart Failure with Mid-Range EF: Current Recommendations and Controversies.

Authors:  Peter Unkovic; Anupam Basuray
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-03

5.  Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.

Authors:  Hiroaki Hiraiwa; Takahiro Okumura; Shinya Shimizu; Yoshihito Arao; Hideo Oishi; Hiroo Kato; Tasuku Kuwayama; Shogo Yamaguchi; Tomoaki Haga; Tsuyoshi Yokoi; Toru Kondo; Yuki Sugiura; Naoaki Kano; Naoki Watanabe; Kenji Fukaya; Kenji Furusawa; Akinori Sawamura; Ryota Morimoto; Kazuro Fujimoto; Masato Mutsuga; Akihiko Usui; Toyoaki Murohara
Journal:  Nagoya J Med Sci       Date:  2020-02       Impact factor: 1.131

6.  Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy.

Authors:  Walter B Schiffer; Andrew Perry; Elena Deych; David L Brown; Luigi Adamo
Journal:  Open Heart       Date:  2021-03

7.  Heart failure ejection fraction class conversions: impact of biomarkers, co-morbidities, and pharmacotherapy.

Authors:  Christian J Lorenzo; Jorge I Conte; Ricardo J Villasmil; Qassem K Abdelal; Derek Pierce; Wilhelmine Wiese-Rometsch; Joel A Garcia-Fernandez
Journal:  ESC Heart Fail       Date:  2022-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.